We would like to thank all the patients who have chosen to participate in this definitive study, as well as the Principal Investigators, investigators and clinical sites across Europe, and partners whose dedication and collaboration make this achievement possible.

This milestone was made possible by dedicated patients and professionals, real effort, and a shared commitment to defining a new evidence-based standard of care for recurrent glioblastoma, a very challenging disease.